By MELINDA J. OVERSTREET for Glasgow News 1 In September 2023, he had been fighting a cold for weeks and weeks. His immune ...

Celltrion USA today announced that STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo), biosimilars referencing PROLIA® ...

For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events (MDEs) known as CRAB: C=Hypercalcemia R=Renal insufficiency A=Anemia B ...

Fresenius Kabi’s fifth and sixth biosimilars Conexxence (denosumab-bnht) and Bomyntra (denosumab-bnht) have launched in the ...

Regular physical activity lowers cancer risk, aids recovery and improves survival. In this expert-led interview, we explore ...

Teclistamab-cqyv is a T-cell-engaging bispecific antibody that targets multiple myeloma cells via the B-cell maturation ...

During a live event, Alfred L. Garfall, MD, discussed talquetamab dosing strategies and efficacy after dose reduction in ...

The findings contradict previous research suggesting high-risk patients with multiple myeloma were more likely to have a ...

Multiple myeloma is almost always preceded by an asymptomatic premalignant stage known as monoclonal gammopathy of undetermined significance (MGUS). About 1% of patients with MGUS progress to SMM ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

Panelists discuss how emerging therapies like CAR T cells and bispecific antibodies may transform frontline treatment by potentially replacing transplant or changing induction regimens, while ...

Multiple myeloma is almost always preceded by an asymptomatic premalignant stage known as monoclonal gammopathy of ...